Sarclisa (isatuximab) – Anti CD38 Targeted Therapy for Myeloma
Sarclisa precision cancer medicine improves survival in advanced Multiple Myeloma - leads to FDA approval
COVID-19 Vaccination in Patients with Blood Cancers
Studies of COVID-19 vaccine effectiveness in myeloma and lymphoma available - vaccine relatively ineffective.
Xpovio - Selinexor Approved by FDA for the Treatment of Multiple Myeloma
Xpovio treatment of Multiple Myeloma receives FDA approval - combination appears superior to Vd with less neuropathy.
Multiple Myeloma
Multiple Myeloma Cancer Connect is a unique resource that brings patients, caregivers, advocates and experts together in a single community where individuals benefit from a blend of expert-authored news and educational programming alongside a robust social network, providing insight into symptoms, diagnosis, treatment, and the support of other individuals being treated at some of the best cancer centers. Multiple Myeloma Cancer Connect offers users expert authored clinically-reviewed information and the perspective of their peers in a safe, objective space, helping to ensure they become empowered in their healthcare journey.
Multiple Myeloma Overviews
Understanding Maintenance Therapy for Multiple Myeloma
Understand the risks-benefits of Revlimid, Ninlaro & Velcade maintenance therapy for Multiple Myeloma; 2019 ASH update.
Understanding Stem Cell Transplants for Multiple Myeloma
2019 ASH update: ASCT treatment of multiple myeloma improves outcomes even in individuals older than 70.;
Overview of Multiple Myeloma
Symptoms, diagnosis and overview of Multiple Myeloma
Treatment of Recurrent Multiple Myeloma
Cancer Connect - Treatment of Recurrent Multiple Myeloma
Multiple Myeloma Treatment
Sarclisa (isatuximab) – Anti CD38 Targeted Therapy for Myeloma
Sarclisa precision cancer medicine improves survival in advanced Multiple Myeloma - leads to FDA approval
Xpovio - Selinexor Approved by FDA for the Treatment of Multiple Myeloma
Xpovio treatment of Multiple Myeloma receives FDA approval - combination appears superior to Vd with less neuropathy.
Bispecific antibodies - the next advance in myeloma treatment
Will bispecific antibodies change the treatment of myeloma?
Talquetamab fo Multiple Myeloma
Talquetamab is a CPRC5DxCD3 Bispecific Antibody being developed for the treatment of myeloma - early results promising.
Multiple Myeloma Survivorship
COVID-19 Vaccination in Patients with Blood Cancers
Studies of COVID-19 vaccine effectiveness in myeloma and lymphoma available - vaccine relatively ineffective.
Advances offer Promise for Multiple Myeloma Patients
Dr. Bill Benisnger M.D. of Swedish Cancer Inst. discusses the growing number of treatment options for Multiple Myeloma
Multiple Myeloma Resources
Useful resources for individuals with Multiple Myeloma
Pesticides Linked to Precancerous Blood Disorder
Pesticides Linked to Precancerous Blood Disorder